Current opportunities:

The following compounds are currently open for out licensing and/or co-development with a strategic partner:

AIC649

Proprietary immune modulator and potential cure for chronic hepatitis B infection.

HSV Pritelivir (AIC316)

Pritelivir is a targeted highly specific solution to treat herpes simplex virus that is also active against virus strains that are resistant to current standard of care.

If you have further questions regarding partnering of our projects please contact: